Pharma & Bio
Technology
Aston Science Makes Another Run at an IPO… October Results for Stomach Cancer Vaccine Will Determine Success or Failure
Aston Science’s cancer vaccine AST-301 (HER2-ICD vaccine) is set to receive its first Phase 2 clinical trial results for stomach cancer this coming October. The company has completed patient recruitme…
Lifestyle
[Exclusive] KMPHARMACEUTICAL Co.,Ltd. Fails to Surpass 20 Billion Won in Market Cap… First Delisting from K-Bio
Following the government’s measures to tighten KOSDAQ delisting requirements, the first delisting case has emerged in the pharmaceutical and biotech industry. KMPHARMACEUTICAL Co.,Ltd., a small but st…
Lifestyle
Aptabio Therapeutics Inc. Takes a Gamble with APX-115 Package Deal… Next Month Will Be a Turning Point for Its “Valuation”
Aptabio Therapeutics Inc.(293780)is making a bold move with a “package deal” as it pursues the technology export of “APX-115” (Isuzinacxib), a pan-NADPH oxidase (Pan-NOX) inhibitor currently under dev…
Technology
MGEN Solutions and BLUEMTEC Jump as Investors Watch for Unusual Moves [K-Bio Pulse]
MGEN Solutions, whose shares began rallying before it disclosed a change in management control, and BLUEMTEC, which jumped nearly 12% without any apparent new catalyst, drew market attention on Tuesda…
Technology
MGEN SOLUTIONS Rallies Ahead of Management Control Disclosure… IlyangPharmaceutical Remains Flat Despite Negative News [Bio Market Watch]
On the 9th, in the domestic pharmaceutical, biotech, and healthcare stock market, MGEN SOLUTIONS(032790)—whose stock price had already surged prior to the announcement of a change in management contro…
Technology
Yuhan Corporation’s New Drug, Stalled for Four Years, Seeks Technology Export… “500 Billion Won Jackpot” Opportunity to Be Decided Within a Year
(Graphic: ChatGPT)
Yuhan(000100)The fate of the new drug candidate “PCS12852” (Yuhan Corporation’s development code: YH12852), which Yuhan Corporation licensed to U.S.-based Processa Pharmaceutica…
Lifestyle
The 'Data on Therapeutic Effects' Kim Seung-won Claimed to Have Seen… Turned Out Not to Be a Formal Research Paper
Kim Seung-won, the nominee for Minister of Justice, addressed the controversy surrounding the request for expedited processing of clinical trials for GenenCell’s COVID-19 treatment “ES16001,” explaini…
Technology
Hair-Loss Drug Hype Spreads to Korea as Hyundai Pharm and JW Shinyak Shares Soar [K-Bio Pulse]
(Image= ChatGPT)
On Sept. 8, shares of Hyundai Pharmaceutical and JW Shinyak extended their rallies as U.S. investor enthusiasm over next-generation hair-loss treatments spilled over into South Ko…
Technology
Amid Expectations for a New U.S. Hair Loss Drug… Even Korean Companies Selling Existing Drugs See ‘Thematic Surge’ [Bio Spotlight]
(Graphic: ChatGPT)
On the 8th, in the domestic pharmaceutical and biotech market, Hyundai pharm(004310)and JW SHINYAK CORPORATION(067290)continued their upward trend for consecutive days. As a U.S…
Technology
[K-Bio Pulse] Sky Labs Hits Limit-Up for the Second Consecutive Session
Korea’s pharmaceutical, biotech, and healthcare sectors saw heavy buying on the 13th, driven by a newly listed medical device company, a global drug theme, and U.S.-originated catalysts. With the KOSD…